- Home
- NSPR vs TCRX Comparison
NSPR vs TCRX Comparison
Compare NSPR & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NSPR | TCRX |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.5M | 63.6M |
| IPO Year | 2009 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NSPR | TCRX |
|---|---|---|
| Price | $1.77 | $1.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $4.00 | ★ $7.00 |
| AVG Volume (30 Days) | 35.1K | ★ 583.3K |
| Earning Date | 03-18-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | ★ N/A | N/A |
| Revenue | $2,310,000.00 | ★ $10,325,000.00 |
| Revenue This Year | $22.91 | N/A |
| Revenue Next Year | $72.30 | $69.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $1.51 | $0.88 |
| 52 Week High | $2.93 | $2.57 |
Technical Indicators
Market Signals| Indicator | NSPR | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 60.49 | 44.89 |
| Support Level | $1.72 | $0.90 |
| Resistance Level | $2.51 | $1.24 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 58.75 | 17.31 |
Price Performance
Historical ComparisonAbout NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.